{
    "organizations": [],
    "uuid": "57de98004797fff4f3b1e08e9c71b3db25d6723b",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-aevi-genomic-medicine-q1-loss-per/brief-aevi-genomic-medicine-q1-loss-per-share-0-15-idUSASC0A2A7",
    "ord_in_thread": 0,
    "title": "BRIEF-Aevi Genomic Medicine Q1 Loss Per Share $0.15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 15 (Reuters) - Aevi Genomic Medicine Inc:\n* AEVI GENOMIC MEDICINE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE\n* Q1 LOSS PER SHARE $0.15 * Q1 EARNINGS PER SHARE VIEW $-0.14 â€” THOMSON REUTERS I/B/E/S\n* CASH AND CASH EQUIVALENTS OF $26.52 MILLION AT MARCH 31, 2018, COMPARED TO $33.73 MILLION AS OF DECEMBER 31, 2017\n* EXPECTS CURRENT CASH BALANCE TO FUND OPERATIONS INTO EARLY 2019 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ",
    "published": "2018-05-15T20:39:00.000+03:00",
    "crawled": "2018-05-16T19:16:43.007+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "aevi",
        "genomic",
        "medicine",
        "inc",
        "aevi",
        "genomic",
        "medicine",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "business",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "cash",
        "cash",
        "equivalent",
        "million",
        "march",
        "compared",
        "million",
        "december",
        "expects",
        "current",
        "cash",
        "balance",
        "fund",
        "operation",
        "early",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}